CAS 144701-48-4 Antihypertensive Telmisartan Powder Telmisartan
Product Description
Product Details
| Product name |
Telmisartan |
| Cas number |
144701-48-4 |
| Apperance |
White to off-white powder |
| MF |
C33H30N4O2 |
| MW |
514.62 |
Telmisartan is a new type of antihypertensive drug, a specific angiotensin II receptor (AT1 type) antagonist, used for the treatment of essential hypertension. It substitutes the angiotensin II receptor with high affinity for the AT1 receptor subtype (the known angiotensin II action site). Telmisartan has no agonist effect at any site of the AT1 receptor and selectively binds to the AT1 receptor, with a long-lasting binding effect. It has no affinity for other receptors (including AT2 and other less characterized AT receptors). The functions of the above-mentioned other receptors are unknown, and the possible receptor overstimulation effects caused by the increase in angiotensin II levels due to telmisartan are also unknown. Telmisartan does not inhibit human plasma renin and does not block ion channels. It does not inhibit angiotensin-converting enzyme II, which can also degrade bradykinin, thereby avoiding the adverse reactions caused by the enhanced effect of bradykinin.
Application&Function
Appearance and solubility
White to off-white crystalline powder, odorless and tasteless. It is soluble in slightly, extremely slightly soluble in almost insoluble in water . Absorption coefficient (E1%1cm) : 509-541
Side effects
In placebo-controlled trials, the total incidence of adverse events of telmisartan (41.4%) was similar to that of placebo (43.9%). The occurrence of adverse events was not correlated with the dose, nor was it related to the patient's gender, age or race. The adverse reactions listed below were accumulated from 5,788 hypertensive patients who received telmisartan treatment in clinical trials.
The adverse reactions listed below were accumulated from 5,788 hypertensive patients who received telmisartan treatment in clinical trials. Adverse reactions are classified by occurrence frequency as follows: very common (> 1/10); Common (> 1/100, < 1/10); Rare (> 1/1000, < 1/100); Rare (> 1/10000, < 1/1000); Very rare (< 1/10,000). General reactions: Common: Back pain (such as sciatica), chest pain, flu-like symptoms, infection symptoms (such as urinary tract infections including cystitis). Rare: Visual abnormalities, excessive sweating. Central and peripheral nervous systems: Common: dizziness. Gastrointestinal system: Common: Abdominal pain, diarrhea, indigestion, gastrointestinal dysfunction. Rare: Dry mouth, flatulence. Musculoskeletal system: Common: Joint pain, leg spasm or leg pain, myalgia. Rare: tenosynovitis-like symptoms. Nervous system: Rare: Anxiety. Respiratory system: Common: Upper respiratory tract infections including pharyngitis and rhinitis. Skin and adnexal system: Common: Skin abnormalities such as eczema. In addition, since the launch of telmisartan, individual cases have reported symptoms such as erythema, itching, syncope, insomnia, depression, stomach discomfort, vomiting, hypotension, bradycardia, tachycardia, breathing difficulties, eosinophilia, thrombocytopenia, weakness, and decreased work efficiency. Similar to other angiotensin II antagonists, angioedema, urticaria and other related adverse reactions have been reported in very few cases. Laboratory findings: Compared with the placebo group, the telmisartan treatment group occasionally found a decrease in hemoglobin or an increase in uric acid. The increase in serum creatinine or liver enzymes at telmisartan was similar to or lower than that at placebo.
Purpose
Antihypertensive drugs, vasodilator antagonists
Specification
ABOUT US
){kind=link}